Infectious diseases are among the greatest global health challenges as shown by recent and past pandemics.
Research focus
Human activities, including urban expansion, intensive farming, and increased global travel, have accelerated the emergence and spread of new infectious diseases. At the same time the growing problem of antimicrobial resistance, is making once-reliable treatments less effective.
Research at LIMS focuses on advancing our understanding of infection processes, improving early detection and monitoring of infections. With the goal of developing novel methods for their prevention and treatment, all with a personalised medicine and health equity lens. Infection and Immunity research explores how the body responds to infections and immune system disorders, with the goal of fine-tuning these responses to improve health.
By understanding the immune mechanisms that drive diseases such as cancer, diabetes, and cardiovascular conditions. LIMS researchers aim to develop targeted therapies that restore balance and prevent harmful inflammation. LIMS is at the forefront of discovering how immune modulation can transform treatment across a wide range of chronic and infectious diseases.
Our group studies the molecular mechanisms underlying Gram-negative bacterial infections to develop antibacterial drugs that are not susceptible to existing resistance mechanisms.
Our goal is to understand the molecular and cellular pathways that initiate and control inflammatory responses, with a particular focus on conditions where inflammation is a central factor, such as infectious diseases like Influenza and COVID-19, and pulmonary disorders including Cystic Fibrosis, asthma, and COPD.
Dr Grant's research focuses on identifying and characterising immune cell responses towards different pathogens, with a particular emphasis on influenza virus, which kills more than half a million people worldwide annually.
Our goal is to understand the molecular and cellular pathways that initiate and control inflammatory responses, with a particular focus on conditions where inflammation is a central factor, such as infectious diseases like Influenza and COVID-19, and pulmonary disorders including Cystic Fibrosis, asthma, and COPD.
Our group aims to advance current understanding of the dynamic host-pathogen interaction along apoptosis–efferocytosis axis and to develop novel therapeutics for respiratory infections, the leading pathogenic causes of global morbidity and mortality.
Our group studies the machinery that control how dying cells can disassemble into smaller pieces, and the importance of cell disassembly in disease settings, to identify new drugs to control this process.
Our group studies the use of bacteriophage as alternatives to antibiotics. We also examine the personalization of medicine to fit a patient's genetic profile, and patient management of medication in the treatment of chronic disease.
